Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator

Nuclear Medicine and Biology

Volumn 32, Issue 7, 2005, Pages 741-747

  Su, Fu Min ^a,c   Beaumier, Paul ^a,d   Axworthy, Don ^a,e   Atcher, Robert ^b   Fritzberg, Alan ^a,e  

^a Poniard Pharmaceuticals Inc   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Shin Nippon Biomedical Laboratories   (United States)

^e NONE   (United States)

Author keywords

Bismuth 212; In situ radionuclide generator; Lead 212; Pre targeting; Radioimmunotherapy; Radionuclide therapy; Tumor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BISMUTH; LEAD 212;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EVALUATION; GAMMA IRRADIATION; GENE TARGETING; KIDNEY; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY;

EID: 27144485779     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2005.06.009     Document Type: Review

References (16)

1. J. Schlom Monoclonal antibodies in cancer therapy V.T. DeVita S. Hellman S.A. Rosenberg Biologic therapy of cancer 1995 Lippincott Philadelphia 180 220
2. S.F. Roseborough Two-step immunological approaches for imaging and therapy Q J Nucl Med 40 1996 234 251
3. D.A. Goodwin Tumor pretargeting: almost the bottom line J Nucl Med 36 1995 876 879
4. P. Abrams, H. Breitz, D. Axworthy, P. Weiden, M. Bjorn, and J. Appelbaum Phase I clinical evaluation of pretargeted 90Y-radioimmunotherapy Proc Am Soc Clin Oncol 14 1995 423
5. H.B. Breitz, P.L. Weiden, P.L. Beaumier, D.B. Axworthy, C. Seiler, and F.M. Su Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin J Nucl Med 4 2000 131 140
6. G. Vaidynathan, and M.R. Zalutsky Targeted therapy using alpha emitters Phys Med Biol 41 1996 1915 1931
7. M.R. Zalutsky, and D.D. Bigner Radioimmunotherapy with α-particle emitting radioimmunoconjugates Acta Oncol 35 1996 373 379
8. J.L. Humm, and L.M. Chin A model of cell inactivation by α-particle internal emitters Radiat Res Phys 13 1993 1767 1773
9. B.J. Allen, and N. Biagojevic Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149 Nucl Med Commun 17 1996 40 47
10. 224Ra Appl Radiat Isot 39 1988 282 286
11. C.L. Ruegg, W.T. Anderson-Berg, M.W. Brechbiel, S. Mirzadeh, O.A. Gansow, and M. Strand Improved in vivo stability and tumor targeting of bismuth-labeled antibody Cancer Res 50 1990 4221 4226
12. 212Bi) therapy Cancer Res 53 1993 5683 5689
13. O.A. Gansow, M.W. Brechbiel, and C.G. Pippin Lead and bismuth complexes of functionalized DTPA ligands and of the polyazacycloalkane-N-acetic DOTA: utility for radioimaging and radioimmunotherapy Antib Immunoconjug Radiopharm 4 1991 413 425
14. 212Pb-DOTA Radiochim Acta 60 1993 1 9
15. International Commission of Radiological Protection, Radionuclide Transformation Energy and intensity of emissions Annals ICRP 1983 Pergamon Press Oxford 11 13
16. F.-M. Su, L.M. Gustavson, D.B. Axworthy, L.L.J. Lyen, L.J. Theodore, and A.R. Fritzberg Characterization of a new Y-90 labeled DOTA-biotin for pretargeting J Nucl Med 36 1995 154